Indian Consensus on the Role and Position of Angiotensin Receptor-neprilysin Inhibitors in the Management of Heart Failure
Hriday Kumar Chopra,Chandrashekhar Ponde,Gurpreet Singh Wander,Tiny Nair,Saumitra Ray,Dinesh Khullar,Navin C Nanda,Jagat Narula,Ravi R Kasliwal,Devinder Singh Rana,Ashok Kirpalani,Jitendrapal Singh Sawhney,Praveen Chandra,Yatin Mehta,Viveka Kumar,Satyendra Tiwari,Arvind K Pancholia,Vijay Kher,Sandeep Bansal,Sanjay Mittal,Praful Kerkar,Prasant Kumar Sahoo,Ramesh Hotchandani,Sunil Prakash,Nagendra Chauhan,Vishal Rastogi,Jabir Abdullakutty,S Shanmugasundaram,Mangesh Tiwaskar,Ajay Sinha,Vittul Gupta,Shishu Shankar Mishra,Satya Narayan Routray,Ashok Kumar Omar,Onkar C Swami,Aparna Jaswal,Shamsad Alam,Rajeev Passey,Rajeeve Rajput,Justin Paul,Aditya Kapoor,Prabhakar Dorairaj,Subhash Chandra,Poonam Malhotra,Vivudh Pratap Singh,Manish Bansal,Sanjay Jain,Priyank Shah,Mohan Bhargava,Ishwarappa Balekundri Vijayalakshmi,Kiron Varghaese,Dharmender Jain,Anupam Goel,Kiran Mahmood,Namrata Gaur,Rohit Tandon,Asha Moorthy,Sheeba George,V K Katyal,R R Mantri,Rahul Mehrotra,Dilip Bhalla,Vinod Mittal,Sarita Rao,Manish Jagia,Harmeet Singh,Surabhi Awasthi,Ameet Sattur,Rekha Mishra,Anand Pandey,Rajeev Chawla,Shalini Jaggi,Blessy Sehgal,Alok Sehgal,Naresh Goel,Ripen Gupta,Samir Kubba,Abhinav Chhabra,Saurabh Bagga,Rajnikant N Shastry
DOI: https://doi.org/10.59556/japi.72.0664
Abstract:The incidence of heart failure (HF) in India is estimated to be 0.5-1.7 cases per 1,000 people per year, and approximately 4,92,000-1.8 million new cases are detected every year. Despite the high rate of mortality associated with HF, most patients do not receive maximal guideline-directed medical therapy (GDMT). Current guidelines advocate early multidrug combination therapy with four classes of drugs, namely, beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose transport protein 2 inhibitors (SGLT-2is), particularly in patients with heart failure with reduced ejection fraction (HFrEF). ARNIs reduce cardiac morbidity and mortality in patients with HFrEF. However, recent data indicated that only 4.8% of patients with HFrEF receive ARNI in India. Hence, at a national consensus on HF meeting, cardiology experts from India formulated a national consensus on the use of ARNI in HF based on current evidence and guidelines. The consensus states that ARNI should be used early in HF, particularly in de novo patients with HFrEF, and those with acute decompensated heart failure (ADHF), irrespective of the presence of low systolic blood pressure (SBP) or diabetes. Moreover, those with HFrEF on renin-angiotensin-aldosterone system (RAAS) inhibitors should be switched to ARNI to reduce the risk of repeated hospitalization for HF, worsening HF, and cardiac death, and to improve the quality of life (QoL). Starting ARNI during the first hospitalization is preferable, and it is safe and effective across all doses. ARNIs can also be used for secondary benefits in patients with preserved ejection fraction [heart failure with preserved ejection fraction (HFpEF)] and HF with mildly reduced EF [heart failure with mildly reduced ejection fraction (HFmrEF)].